Previous 10 | Next 10 |
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that it has sold...
Extensive biotech finance and investor relations expertise includes leadership roles at Editas Medicine and Novartis Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined con...
Extensive biotech finance and investor relations expertise includes leadership roles at Editas Medicine and Novartis PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicate...
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note tha...
Phase 1/2a clinical trial expected to begin in first half of 2021 PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”) is pleased to note that its Founded Entity, Vor Biopharma , a clinical-stage cell therapy company...
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairman Michael Davin, former CEO of Cynosure, joins Board of Directors PureTech Health plc (LSE: PRTC, NA...
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairman Michael Davin, former CEO of Cynosure, joins Board of Directors Follica Inc. (“Follica”...
Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company...
Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for...
Experienced financial analyst and biotech executive added to PureTech’s strong leadership team PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discoverin...
News, Short Squeeze, Breakout and More Instantly...
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated...
2024-06-27 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, confirms that the Tender Offer announced by the Company on 20 May 2024 is now ...